View ValuationGlaxoSmithKlineE 将来の成長Future 基準チェック /06現在、 GlaxoSmithKlineEの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長13.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 11GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026, at 15:30 Egypt Standard Time. Location: cairo Egyptお知らせ • Dec 31GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026GlaxoSmithKline S.A.E announced Annual dividend of EGP 1.0000 per share payable on January 14, 2026, ex-date on January 12, 2026 and record date on January 13, 2026.Reported Earnings • May 15First quarter 2025 earnings released: EPS: ج.م0.71 (vs ج.م0.11 loss in 1Q 2024)First quarter 2025 results: EPS: ج.م0.71 (up from ج.م0.11 loss in 1Q 2024). Revenue: ج.م993.9m (up 39% from 1Q 2024). Net income: ج.م59.1m (up ج.م68.1m from 1Q 2024). Profit margin: 5.9% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 06GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025, at 15:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م0.16 (vs ج.م0.33 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.16 (down from ج.م0.33 in 3Q 2023). Revenue: ج.م787.1m (up 37% from 3Q 2023). Net income: ج.م13.3m (down 51% from 3Q 2023). Profit margin: 1.7% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ج.م45.80, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 104% over the past three years.Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م36.23, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 50% over the past three years.Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: ج.م1.22 (vs ج.م0.07 in 2Q 2023)Second quarter 2024 results: EPS: ج.م1.22 (up from ج.م0.07 in 2Q 2023). Revenue: ج.م642.4m (up 19% from 2Q 2023). Net income: ج.م101.5m (up ج.م95.8m from 2Q 2023). Profit margin: 16% (up from 1.1% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 7% per year.Upcoming Dividend • Jul 11Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.1%).Reported Earnings • May 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ج.م713.8m (up 55% from 1Q 2023). Net loss: ج.م8.99m (down 165% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (ج.م2.60b market cap, or US$54.1m).New Risk • Apr 28New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م2.58b market cap, or US$53.9m).Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ج.م29.32, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 9x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 29% over the past three years.Reported Earnings • Mar 07Full year 2023 earnings releasedFull year 2023 results: Revenue: ج.م2.24b (up 23% from FY 2022). Net income: ج.م74.1m (up ج.م205.1m from FY 2022). Profit margin: 3.3% (up from net loss in FY 2022).Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م42.66, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 10x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 40% over the past three years.New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م2.95b market cap, or US$95.3m).New Risk • Aug 30New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Market cap is less than US$100m (ج.م2.61b market cap, or US$84.4m).Upcoming Dividend • Jun 27Upcoming dividend of ج.م0.75 per share at 2.3% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 06 July 2023. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (7.6%). Lower than average of industry peers (3.6%).Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ج.م37.45, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 376% over the past three years.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ج.م28.01, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 362% over the past three years.Upcoming Dividend • Dec 28Upcoming dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 04 January 2023. Payment date: 08 January 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.8%).Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م35.37, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 93% over the past three years.Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to ج.م29.39, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 61% over the past three years.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Sep 13Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 22 September 2022. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (4.1%).Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م23.33, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 38% over the past year.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م20.08, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 6.1% over the past three years.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م23.90, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 44% over the past year.Upcoming Dividend • Jun 28Upcoming dividend of ج.م0.50 per shareEligible shareholders must have bought the stock before 05 July 2021. Payment date: 07 July 2021. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.2%).お知らせ • Mar 12Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC).Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited on January 25, 2021. The transaction would be subject to satisfaction of certain conditions, including but not limited to (i) the completion of satisfactory due diligence, (ii) the entry into definitive and binding legal documents; and (iii) obtaining the approval(s) of the regulatory authorities. As of January 27, 2021, The board of directors of GlaxoSmithKline S.A.E agreed to allow Hikma Pharmaceuticals Plc to conduct due diligence. Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC) on March 11, 2021.お知らせ • Feb 02Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline SharesGlaxo Group Limited received letter from Acdima - Arab Co. For Drugs Industries & Medical Appliances expressing interest in positioning an offer for potential acquisition of shares of majority shareholder in GlaxoSmithKline S.A.E (CASE:BIOC).Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improved over the past weekAfter last week's 29% share price gain to ج.م21.28, the stock is trading at a trailing P/E ratio of 8.2x, up from the previous P/E ratio of 6.4x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total return to shareholders over the past three years is a loss of 9.7%.Is New 90 Day High Low • Jan 27New 90-day high: ج.م19.35The company is up 24% from its price of ج.م15.59 on 28 October 2020. The Egyptian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.Is New 90 Day High Low • Dec 21New 90-day low: ج.م15.15The company is down 1.0% from its price of ج.م15.35 on 22 September 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Reported Earnings • Nov 17Third quarter 2020 earnings released: ج.م0.17 loss per shareThe company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ج.م483.6m (up 12% from 3Q 2019). Net loss: ج.م14.6m (down 138% from profit in 3Q 2019).Is New 90 Day High Low • Nov 02New 90-day low: ج.م15.22The company is down 11% from its price of ج.م17.06 on 04 August 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 04New 90-day high: ج.م18.34The company is up 9.0% from its price of ج.م16.82 on 06 July 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、GlaxoSmithKlineE は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CASE:BIOC - アナリストの将来予測と過去の財務データ ( )EGP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20253,73121364241N/A9/30/20253,74198-198-58N/A6/30/20253,519146-5363N/A3/31/20253,271242-207-109N/A12/31/20242,991174-528-404N/A9/30/20242,80712035121N/A6/30/20242,60013369160N/A3/31/20242,49338309405N/A12/31/20232,24060225302N/A9/30/20232,131-139506597N/A6/30/20232,097-11743115N/A3/31/20231,914-120-564-507N/A12/31/20221,823-1149871,036N/A9/30/20222,099193543579N/A6/30/20221,959193849884N/A3/31/20222,0422091,3831,422N/A12/31/20211,812155156192N/A9/30/20211,549-4074125N/A6/30/20211,627-104116171N/A3/31/20211,699-423182N/A12/31/20201,99328-55-1N/A9/30/20201,930177-102-12N/A6/30/20201,878230-172-78N/A3/31/20201,764175-10038N/A12/31/20191,704143-196-63N/A9/30/20191,690-13N/A167N/A6/30/20191,64519N/A186N/A3/31/20191,63032N/A136N/A12/31/20181,62350N/A323N/A9/30/20181,563-3N/A329N/A6/30/20181,55659N/A84N/A3/31/20181,508106N/A128N/A12/31/20171,453102N/A-469N/A9/30/20171,350162N/A-668N/A6/30/20171,238135N/A-369N/A3/31/20171,20787N/A-384N/A12/31/20161,166-4N/A79N/A9/30/20161,116270N/A75N/A6/30/20161,094138N/A81N/A3/31/20161,08073N/A120N/A12/31/20151,01069N/A169N/A9/30/20151,031-96N/A230N/A6/30/20151,054-44N/A159N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BIOCの予測収益成長が 貯蓄率 ( 15.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BIOCの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BIOCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BIOCの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BIOCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BIOCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 10:58終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GlaxoSmithKline S.A.E 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 11GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026GlaxoSmithKline S.A.E, Annual General Meeting, May 03, 2026, at 15:30 Egypt Standard Time. Location: cairo Egypt
お知らせ • Dec 31GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026GlaxoSmithKline S.A.E announced Annual dividend of EGP 1.0000 per share payable on January 14, 2026, ex-date on January 12, 2026 and record date on January 13, 2026.
Reported Earnings • May 15First quarter 2025 earnings released: EPS: ج.م0.71 (vs ج.م0.11 loss in 1Q 2024)First quarter 2025 results: EPS: ج.م0.71 (up from ج.م0.11 loss in 1Q 2024). Revenue: ج.م993.9m (up 39% from 1Q 2024). Net income: ج.م59.1m (up ج.م68.1m from 1Q 2024). Profit margin: 5.9% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year and the company’s share price has also increased by 16% per year.
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 06GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025GlaxoSmithKline S.A.E, Annual General Meeting, May 28, 2025, at 15:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • Nov 16Third quarter 2024 earnings released: EPS: ج.م0.16 (vs ج.م0.33 in 3Q 2023)Third quarter 2024 results: EPS: ج.م0.16 (down from ج.م0.33 in 3Q 2023). Revenue: ج.م787.1m (up 37% from 3Q 2023). Net income: ج.م13.3m (down 51% from 3Q 2023). Profit margin: 1.7% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 14Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ج.م45.80, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 104% over the past three years.
Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م36.23, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 50% over the past three years.
Reported Earnings • Aug 18Second quarter 2024 earnings released: EPS: ج.م1.22 (vs ج.م0.07 in 2Q 2023)Second quarter 2024 results: EPS: ج.م1.22 (up from ج.م0.07 in 2Q 2023). Revenue: ج.م642.4m (up 19% from 2Q 2023). Net income: ج.م101.5m (up ج.م95.8m from 2Q 2023). Profit margin: 16% (up from 1.1% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 7% per year.
Upcoming Dividend • Jul 11Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 18 July 2024. Payment date: 22 July 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 2.6%. Lower than top quartile of Egyptian dividend payers (7.2%). Lower than average of industry peers (3.1%).
Reported Earnings • May 18First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ج.م713.8m (up 55% from 1Q 2023). Net loss: ج.م8.99m (down 165% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
New Risk • May 03New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (ج.م2.60b market cap, or US$54.1m).
New Risk • Apr 28New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (ج.م2.58b market cap, or US$53.9m).
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ج.م29.32, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 9x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 29% over the past three years.
Reported Earnings • Mar 07Full year 2023 earnings releasedFull year 2023 results: Revenue: ج.م2.24b (up 23% from FY 2022). Net income: ج.م74.1m (up ج.م205.1m from FY 2022). Profit margin: 3.3% (up from net loss in FY 2022).
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م42.66, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 10x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 40% over the past three years.
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (ج.م2.95b market cap, or US$95.3m).
New Risk • Aug 30New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 24% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risk Market cap is less than US$100m (ج.م2.61b market cap, or US$84.4m).
Upcoming Dividend • Jun 27Upcoming dividend of ج.م0.75 per share at 2.3% yieldEligible shareholders must have bought the stock before 04 July 2023. Payment date: 06 July 2023. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (7.6%). Lower than average of industry peers (3.6%).
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ج.م37.45, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 376% over the past three years.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ج.م28.01, the stock trades at a trailing P/E ratio of 11.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 362% over the past three years.
Upcoming Dividend • Dec 28Upcoming dividend of ج.م3.00 per shareEligible shareholders must have bought the stock before 04 January 2023. Payment date: 08 January 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.8%).
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م35.37, the stock trades at a trailing P/E ratio of 14.2x. Average trailing P/E is 5x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 93% over the past three years.
Valuation Update With 7 Day Price Move • Nov 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to ج.م29.39, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 61% over the past three years.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Sep 13Upcoming dividend of ج.م0.75 per shareEligible shareholders must have bought the stock before 20 September 2022. Payment date: 22 September 2022. Trailing yield: 2.1%. Lower than top quartile of Egyptian dividend payers (10%). Lower than average of industry peers (4.1%).
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ج.م23.33, the stock trades at a trailing P/E ratio of 11x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 38% over the past year.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م20.08, the stock trades at a trailing P/E ratio of 9.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 6.1% over the past three years.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م23.90, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 44% over the past year.
Upcoming Dividend • Jun 28Upcoming dividend of ج.م0.50 per shareEligible shareholders must have bought the stock before 05 July 2021. Payment date: 07 July 2021. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (8.0%). Lower than average of industry peers (3.2%).
お知らせ • Mar 12Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC).Hikma Pharmaceuticals PLC (LSE:HIK) entered into a non-binding term sheet to acquire 91.2% stake in GlaxoSmithKline S.A.E (CASE:BIOC) from Glaxo Group Limited on January 25, 2021. The transaction would be subject to satisfaction of certain conditions, including but not limited to (i) the completion of satisfactory due diligence, (ii) the entry into definitive and binding legal documents; and (iii) obtaining the approval(s) of the regulatory authorities. As of January 27, 2021, The board of directors of GlaxoSmithKline S.A.E agreed to allow Hikma Pharmaceuticals Plc to conduct due diligence. Hikma Pharmaceuticals PLC (LSE:HIK) cancelled the acquisition of GlaxoSmithKline S.A.E (CASE:BIOC) on March 11, 2021.
お知らせ • Feb 02Glaxo Group Receives Letter from ACDIMA for Acquisition of Glaxosmithkline SharesGlaxo Group Limited received letter from Acdima - Arab Co. For Drugs Industries & Medical Appliances expressing interest in positioning an offer for potential acquisition of shares of majority shareholder in GlaxoSmithKline S.A.E (CASE:BIOC).
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improved over the past weekAfter last week's 29% share price gain to ج.م21.28, the stock is trading at a trailing P/E ratio of 8.2x, up from the previous P/E ratio of 6.4x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total return to shareholders over the past three years is a loss of 9.7%.
Is New 90 Day High Low • Jan 27New 90-day high: ج.م19.35The company is up 24% from its price of ج.م15.59 on 28 October 2020. The Egyptian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Dec 21New 90-day low: ج.م15.15The company is down 1.0% from its price of ج.م15.35 on 22 September 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Reported Earnings • Nov 17Third quarter 2020 earnings released: ج.م0.17 loss per shareThe company reported a soft third quarter result with weaker earnings and control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: ج.م483.6m (up 12% from 3Q 2019). Net loss: ج.م14.6m (down 138% from profit in 3Q 2019).
Is New 90 Day High Low • Nov 02New 90-day low: ج.م15.22The company is down 11% from its price of ج.م17.06 on 04 August 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 04New 90-day high: ج.م18.34The company is up 9.0% from its price of ج.م16.82 on 06 July 2020. The Egyptian market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period.